Durvalumab for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Mar 2022: Trial registered, NCT05303532
  2. 19 Apr 2022: Trial started, NCT05303532

The trials

NCT05303532: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

State
Under way
Phase
Phase 3
People
214 planned
Started
19 Apr 2022
Primary completion
31 Dec 2026
Arms
Durvalumab
Results
None posted
  1. 31 Mar 2022: Trial registered
  2. 19 Apr 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Imfinzi, MEDI4736 (Durvalumab).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.